Freedom Investment Management’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-5,399
| Closed | -$297K | – | 216 |
|
|
2025
Q2 | $297K | Sell |
5,399
-285
| -5% | -$16.8K | 0.02% | 593 |
|
|
2025
Q1 | $402K | Buy |
5,684
+662
| +13% | +$44.5K | 0.03% | 487 |
|
|
2024
Q4 | $330K | Buy |
5,022
+184
| +4% | +$12.3K | 0.03% | 561 |
|
|
2024
Q3 | $340K | Sell |
4,838
-350
| -7% | -$29.3K | 0.03% | 558 |
|
|
2024
Q2 | $427K | Buy |
5,188
+639
| +14% | +$53.2K | 0.04% | 478 |
|
|
2024
Q1 | $397K | Sell |
4,549
-383
| -8% | -$34.3K | 0.03% | 504 |
|
|
2023
Q4 | $476K | Sell |
4,932
-222
| -4% | -$19.6K | 0.04% | 448 |
|
|
2023
Q3 | $456K | Sell |
5,154
-134
| -3% | -$11.9K | 0.06% | 386 |
|
|
2023
Q2 | $458K | Sell |
5,288
-418
| -7% | -$39.3K | 0.05% | 419 |
|
|
2023
Q1 | $555K | Sell |
5,706
-352
| -6% | -$36.5K | 0.06% | 376 |
|
|
2022
Q4 | $627K | Sell |
6,058
-212
| -3% | -$19.9K | 0.07% | 343 |
|
|
2022
Q3 | $531K | Sell |
6,270
-265
| -4% | -$23.6K | 0.06% | 400 |
|
|
2022
Q2 | $542K | Sell |
6,535
-151
| -2% | -$12K | 0.06% | 427 |
|
|
2022
Q1 | $515K | Sell |
6,686
-513
| -7% | -$42.9K | 0.05% | 462 |
|
|
2021
Q4 | $636K | Sell |
7,199
-154
| -2% | -$12.7K | 0.05% | 463 |
|
|
2021
Q3 | $568K | Sell |
7,353
-322
| -4% | -$25.4K | 0.04% | 469 |
|
|
2021
Q2 | $640K | Sell |
7,675
-480
| -6% | -$38K | 0.05% | 463 |
|
|
2021
Q1 | $616K | Sell |
8,155
-4,188
| -34% | -$342K | 0.05% | 453 |
|
|
2020
Q4 | $1.08M | Sell |
12,343
-1,691
| -12% | -$134K | 0.12% | 175 |
|
|
2020
Q3 | $1.07M | Sell |
14,034
-997
| -7% | -$101K | 0.12% | 167 |
|
|
2020
Q2 | $1.85M | Sell |
15,031
-3,277
| -18% | -$326K | 0.2% | 108 |
|
|
2020
Q1 | $1.58M | Buy |
18,308
+557
| +3% | +$48K | 0.14% | 138 |
|
|
2019
Q4 | $1.5M | Sell |
17,751
-2,257
| -11% | -$170K | 0.13% | 155 |
|
|
2019
Q3 | $1.35M | Sell |
20,008
-3,323
| -14% | -$256K | 0.12% | 169 |
|
|
2019
Q2 | $2M | Sell |
23,331
-1,385
| -6% | -$118K | 0.17% | 129 |
|
|
2019
Q1 | $2.2M | Sell |
24,716
-445
| -2% | -$41.2K | 0.18% | 123 |
|
|
2018
Q4 | $2.14M | Sell |
25,161
-1,868
| -7% | -$178K | 0.17% | 115 |
|
|
2018
Q3 | $2.59M | Sell |
27,029
-1,093
| -4% | -$109K | 0.16% | 109 |
|
|
2018
Q2 | $2.65M | Buy |
28,122
+9,593
| +52% | +$840K | 0.16% | 107 |
|
|
2018
Q1 | $1.5M | Buy |
18,529
+337
| +2% | +$28.9K | 0.08% | 249 |
|
|
2017
Q4 | $1.62M | Buy |
18,192
+514
| +3% | +$44.7K | 0.08% | 207 |
|
|
2017
Q3 | $1.65M | Sell |
17,678
-853
| -5% | -$75.4K | 0.09% | 185 |
|
|
2017
Q2 | $1.68M | Buy |
18,531
+106
| +0.6% | +$9.64K | 0.1% | 163 |
|
|
2017
Q1 | $1.62M | Sell |
18,425
-2,401
| -12% | -$214K | 0.09% | 166 |
|
|
2016
Q4 | $1.73M | Sell |
20,826
-5,297
| -20% | -$456K | 0.11% | 124 |
|
|
2016
Q3 | $2.42M | Sell |
26,123
-789
| -3% | -$74.3K | 0.15% | 77 |
|
|
2016
Q2 | $2.09M | Buy |
26,912
+1,160
| +5% | +$98.6K | 0.14% | 78 |
|
|
2016
Q1 | $2.12M | Buy |
25,752
+439
| +2% | +$35.7K | 0.15% | 76 |
|
|
2015
Q4 | $2.65M | Sell |
25,313
-7,881
| -24% | -$823K | 0.2% | 57 |
|
|
2015
Q3 | $185K | Buy |
33,194
+16,543
| +99% | +$2.21M | 0.02% | 616 |
|
|
2015
Q2 | $2.28M | Buy |
16,651
+4,823
| +41% | +$598K | 0.23% | 56 |
|
|
2015
Q1 | $1.47M | Buy |
11,828
+5,840
| +98% | +$619K | 0.16% | 88 |
|
|
2014
Q4 | $541K | Buy |
+5,988
| New | +$498K | 0.07% | 265 |
|
Other funds holding BMRN
Freedom Investment Management's BMRN Position: Q3 2025 in Review
Freedom Investment Management sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2025, closing a stake of 5,399 shares — an estimated $297K sold.
Freedom Investment Management first reported a position in BMRN in Q4 2014 and held it in 43 quarters. The position peaked at $2.65M in Q4 2015. 576 funds tracked by Wall St. Rank hold BMRN as of Q3 2025.
- Freedom Investment Management reported no remaining BioMarin Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
- Freedom Investment Management sold 5,399 BioMarin Pharmaceuticals shares in Q3 2025, an estimated $297K.
- Freedom Investment Management first reported a position in BioMarin Pharmaceuticals in Q4 2014 and held it in 43 quarters.
- Freedom Investment Management's BioMarin Pharmaceuticals position peaked at $2.65M in Q4 2015.
- 576 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2025.
Based on Freedom Investment Management's 13F filing for Q3 2025, filed 14 Nov 2025.